US-based molecular diagnostics firm Asuragen has launched the QuantideX qPCR BCR-ABL minor Kit designed to monitor molecular response in patients with chronic myeloid leukaemia (CML).
Based on its predecessor, QuantideX qPCR BCR-ABL IS Kit, which quantifies major BCR-ABL1 fusion transcripts in the disease, the new kit will measure minor BCR-ABL1 fusion transcripts.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Asuragen diagnostic systems feature a combination of chemistry and software to provide simple and reliable performance through instrument platforms.
The QuantideX BCR-ABL line is intended to allow laboratories to monitor patients with leukaemia, enabling them to obtain the latest tyrosine-kinase inhibitor (TKI) treatments.
With multiplexed assay design, the kits use a single reaction to identify fusion transcripts and controls, while their Armored RNA-based standards ensure precise RNA quantification.
Asuragen president and CEO Matthew McManus said: “For CML patients with sustained responses to TKI therapy, the goal of treatment-free remission is gaining momentum in the clinical community.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Monitoring during therapy cessation will require accurate, reproducible, and highly sensitive measurement of disease burden.
“The expanded QuantideX BCR-ABL portfolio demonstrates our commitment and focus on changing how diagnostics impact care.”
Both the major and minor kits are reported to possess clinical sensitivities that can identify even 0.002% and 0.0025% ratio of residual disease amounts using human RNA.
Following a review of ABL1 copy number, the firm is also increasing the capabilities of QuantideX qPCR BCR-ABL IS Kit’s accompanying analysis software QuantideX Reporter to enable reporting of accurate clinical sensitivity for CML patient disease burden.
